Trial of a preferential Phosphodiesterase 4B Inhibitor for idiopathic pulmonary fibrosis.
16 May, 2022 | 02:32h | UTCTrial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a placebo-controlled trial, treatment with the phosphodiesterase 4 inhibitor BI 1015550 prevented a decrease in lung function over a 12-week period in patients with idiopathic pulmonary fibrosis. #ATS2022 https://t.co/G60NO2ntRR pic.twitter.com/pUNqnBhhPB
— NEJM (@NEJM) May 15, 2022